Medigus Receives First Purchase Order From Izasa Hospital in Spain for Its MUSE™ System

OMER, Israel, October 16, 2017 – Medigus Ltd. (NASDAQ: MDGS) (TASE: MDGS), a medical device company developing minimally invasive endosurgical tools and a leader in direct visualization technology, today announced that Izasa Hospital, S.L.U., a distributor of medical products in the hospital sector, has provided an initial purchase order (PO) for the Medigus Ultrasonic Surgical Endostapler, or MUSE™ system. The PO covers the cost of a MUSE™ system console and endoscopic device, which will be available for use on patients suffering from gastroesophageal reflux disease (GERD).

The MUSE™ system is a single-use flexible transoral stapler that merges the latest advancement in microvisual, ultrasonic and surgical stapling. The device comes equipped with an ultrasonic sight and range finder and a micro ScoutCam™ CMOS camera, which enables a single physician to perform an incisionless transoral fundoplication, the procedure intended to treat the anatomical cause of GERD. As the device requires no incisions, patients generally report greater comfort during the procedure and experience reduced hospital stays by up to 50% over invasive fundoplication procedures.

“We are pleased that Izasa Hospital has adopted the MUSE™ system as a minimally-invasive treatment option, which offers an alternative for GERD patients who can no longer rely on drug therapy,” said Chris Rowland, CEO of Medigus. “This purchase order is an important milestone in our business development initiative, and we are excited to offer this interventional endoscopic treatment in Spain, a key market that will benefit from this minimally invasive and cost efficient option.”

According to experts, as much as twenty-six percent of Europe’s population suffers from GERD at least once per week . GERD occurs when the base of the lower esophageal sphincter does not properly close after swallowing, which allows acid to back up (or reflux) in to the esophagus, causing discomfort. The acid-reducing medications called proton pump inhibitors may offer patients temporary relief; however, they do not treat that anatomical source of GERD, leaving the opportunity for the disease to progress into a more severe condition.

Those who experience symptoms such as heartburn or regurgitation twice a week or more, may be at risk for persistent GERD.